Introduction {#sec1}
============

Patients with COPD have frequent exacerbations which lead to increased airway inflammation and often subsequent hospitalization.[@bib1] Bacteria are associated with approximately 50% of exacerbations.[@bib2], [@bib3] A number of studies have identified viral infections of the respiratory tract as precipitating agents. Studies using serology and viral culture identified respiratory viruses in 30% of patients during acute exacerbations of COPD.[@bib4] With the development of more sensitive molecular tests the role of viruses in COPD has been better defined. Walsh et al. identified several common respiratory viruses in a cohort of patients with COPD or congestive cardiac failure.[@bib5] Viruses were identified by serology and viral culture methods. Significant outcomes in terms of hospitalisation were seen for respiratory syncytial virus (RSV) and influenza A infected patients. Greenberg et al., using serology and viral culture, showed that in 23% of cases of hospitalisation of COPD patients a virus was detected and that the mean time to return to symptomatic baseline was 2 weeks.[@bib6] The most common viruses identified were of the picornavirus classification (rhinoviruses).

Several studies have used PCR for the diagnosis of viral infection. Initially, in 2000 Seemungal et al. examined 33 patients with COPD when stable and subsequently during an exacerbation.[@bib7] Ten of 43 exacerbations were associated with rhinovirus infection. Higher symptom scores and sputum interleukin-6 levels were seen with rhinovirus exacerbations. Seemungal et al. went on to show respiratory viral infection in 39% of exacerbations of COPD.[@bib8] Viral infection was associated with a more severe exacerbation, and in patients who had a higher frequency of exacerbations, i.e. those with the poorest lung function. Patients were reviewed in convalescence at 4--6 weeks. The majority (58%) of these viruses were rhinovirus (i.e. 23% of COPD exacerbations). Plasma IL-6 levels were elevated in all exacerbations, and levels were significantly increased in the virus positive group when comparison was made with those in whom no virus was detected.

Rohde et al. used PCR to detect viruses in patients with exacerbations of COPD. A respiratory virus was detected in 56% of cases in comparison to 19% of control subjects with stable COPD.[@bib9] The majority of viruses detected were picornaviruses. The most recent study from Beckham et al. combined specimens obtained for two previous studies for analysis by PCR.[@bib10] They detected a respiratory viral infection in 42% of acute respiratory illnesses. Respiratory viral infection in COPD patients during exacerbation has been associated with longer median symptom recovery time in comparison to exacerbations in which a viral agent was not identified (13 days versus 6 days respectively).[@bib8]

The hypothesis tested in the present study was that acute respiratory viral infection is implicated in the pathogenesis of COPD exacerbations. The aims of the present study were to examine respiratory specimens for the presence of respiratory viruses in patients with COPD whilst stable and also during exacerbations.

Methods {#sec2}
=======

Subjects {#sec2.1}
--------

This study was approved by the Queen\'s University Belfast ethics committee and all patients gave written consent. The patient groups described in this paper have been described in other related publications. Patients hospitalised with exacerbations of COPD were recruited within 24 h of presentation over a 2-year period. A further group of stable COPD patients were also recruited. Stability was defined as no change in respiratory symptoms or alteration in therapy in the previous 8 weeks. Patient\'s symptoms were recorded in a binary format. Spirometry was performed, the best of 3 reproducible readings was taken (Vitalograph spirometer, Vitalograph, Buckingham, UK).[@bib11] Spirometry was repeated after nebulised beta agonist (salbutamol 2.5 mg). Any patients with significant improvement in FEV~1~ (\>200 ml/15%) were excluded. Those patients with a history of bronchiectasis, neoplastic process or other serious concomitant disease were excluded.

Definitions {#sec2.2}
-----------

COPD and assessment of severity was classified according to the GOLD criteria.[@bib12] Exacerbation of COPD was classified according to the GOLD criteria with symptoms of increased dyspnoea, increased cough or increased sputum production.[@bib13] Stable COPD was classified according to the GOLD criteria without any symptoms of exacerbation or changes in treatment within the last 8 weeks.

Samples {#sec2.3}
-------

Sputum samples were obtained either by spontaneous production or following nebulised hypertonic saline. Briefly, 4 ml of 3% saline was nebulised via an air driven nebuliser. Every 5 min spirometry was repeated to measure FEV~1~, and nebulisation continued if FEV~1~ had not fallen by more than 20%. This was continued up to 20 min. All sputum expectorated was collected. All samples were processed within 2 h. Specimens were mixed with 4 volumes of 0.1% dithiothreitol (Sigma, Poole, UK) and shaken in an orbital incubator (Gallenkamp, Loughborough, UK) for 15 min at 37 °C followed by the addition of 4 volumes of phosphate buffered saline and shaken for a further 5 min. The resulting suspension was then filtered through 50 μm Nylon Gauze (Lockertex, Warrington, UK) and spun down at 1000 ×  *g* for 10 min. After removing the supernatant the cell pellet was resuspended in Lysis Buffer (Qiagen, Crawley, UK). Total nucleic acid extraction was performed on 200 μl of sputum sample suspended in Lysis Buffer (QIAamp DNA Blood Mini Kit).

Polymerase chain reaction {#sec2.4}
-------------------------

Extracted samples were screened for common respiratory viruses (rhinovirus, human metapneumovirus, influenza A H1 and H3, influenza B, RSV A and B, coronavirus 229E, adenovirus and parainfluenza 1, 2 and 3) using an eight-well multiplexed, nested PCR system ([Fig. 1](#fig1){ref-type="fig"} ).[@bib14] A positive control was used for each set of patient\'s tests. Mastermix and PCR cycling conditions are listed in the Supplementary material([appendix A1 and A2](#appsecb1){ref-type="sec"} respectively). Tests results were accepted as being valid when the positive control tested positive with correct sized product(s). A positive result was noted when second (or first and second) round products were noted and confirmed as being the correct size. Indeterminate test results were repeated. This method allowed rapid testing of clinical specimens for multiple viruses with sensitive and specific assays.Figure 1Nested PCR for respiratory virus screen with 1st and 2nd round products. Specimen positive for influenza A H3 (lane 4), with positive control of parainfluenza 1 (lane 8). Molecular weight markers flank specimens.

Statistical analysis {#sec2.5}
--------------------

A power calculation was performed to determine study group sizes. Assuming a respiratory virus detection rate of 30% amongst COPD patients during exacerbations and 10% detection when stable a power calculation was performed using EpiInfo™ version 6. Using a confidence value of 95% with a power of 80% and a 2:1 ratio of group sizes, 111 patients with COPD exacerbations and 56 stable COPD subjects were required.

Normally distributed data were presented as mean ± standard deviation, whilst non-parametric data were expressed as median and inter quartile ranges. Normally distributed continuous variables were compared by *t*-test; otherwise the differences were assessed by the Mann--Whitney *U*-test. For discrete variables frequencies and percentages were reported and groups compared using the chi squared test. A significance level of 5% was chosen. Statistical analysis was carried out using SPSS (Chicago, IL) version 10.0.

Results {#sec3}
=======

Subjects {#sec3.1}
--------

A total of 220 subjects were recruited in this study ([Table 1](#tbl1){ref-type="table"} ); 136 were seen during an acute exacerbation, and 68 were recruited when stable. An additional 16 non-obstructed smokers with a FEV~1~ and FVC within the normal range were recruited. Patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} ; the exacerbated and stable COPD groups were of similar age, sex, FEV~1~, tobacco use, baseline MRC score, inhaled steroid and body mass index (BMI) and pack years of tobacco use.Table 1Patient demographics and results of investigationsMeasurementPatient groupExacerbated COPDStable COPDNon-obstructed smokersNo. patients1366816Sex (M/F)64/7230/384/12Age70.2 ± 9.466.3 ± 9.452.2 ± 7.6FEV~1~, litres (% Pred)0.84 ± 0.47 (39 ± 20)1.00 ± 0.53 (48 ± 22)2.60 ± 0.56 (105 ± 11)Tobacco (packs/year)48.0 ± 39.2[a](#tblfn1){ref-type="table-fn"}42.2 ± 26.0[b](#tblfn2){ref-type="table-fn"}44.0 ± 21.5C reactive protein14.8 (5.0--70.2)[c](#tblfn3){ref-type="table-fn"}5.0 (5.0--8.4)5.0 (5.0--5.0)White cell count10.9 ± 3.7[c](#tblfn3){ref-type="table-fn"}8.7 ± 2.68.6 ± 2.7Neutrophil count7.9 ± 3.6[c](#tblfn3){ref-type="table-fn"}5.4 ± 2.34.9 ± 2.2BMI25.4 ± 6.126.0 ± 5.229.0 ± 5.3[^1][^2][^3]Table 2Patient medicationMeasurementPatient groupExacerbated COPDStable COPDNon-obstructed smokersNo. patients1366816Short acting β2 agonist80400Long acting β2 agonist57420Inhaled steroid94530Inhaled steroid (BDP)1040 ± 727949 ± 588--Oral theophylline45230Theophylline (mg)482 ± 189524 ± 198--Nebulised therapy86280Home oxygen39110Maintenance oral steroids960

Blood investigations {#sec3.2}
--------------------

CRP and white cell count (WCC) were significantly elevated during exacerbation when compared to stable COPD patients. CRP levels were 14.8 mg/dl (5.0--70.2 mg/dl) at exacerbation and 5.0 mg/dl (5.0--8.4 mg/dl) in stable patients (*p*  \< 0.0001). The WCC increased from 8.7 ± 2.6 to 10.9 ± 3.7 × 10^3^/l in exacerbations of COPD (*p*  \< 0.0001). Similarly the neutrophil count increased from 5.4 ± 2.3 to 7.9 ± 3.6 during exacerbations (*p*  \< 0.0001). Duration of stay in hospital correlated (Pearson's) with the CRP level on admission, *r*  = 0.22, *p*  \< 0.05.

Patients' symptoms {#sec3.3}
------------------

The majority of patients described symptoms of increased dyspnoea, cough along with increased sputum volume and purulence during exacerbations ([Table 3](#tbl3){ref-type="table"} ). The presence of fever was associated with the identification in the same patient, *p*  \< 0.05. The majority of patients were MRC score 5 during exacerbations.Table 3Patient symptoms during exacerbationsMeasurementRecorded during an exacerbationTotal number of patients136Increased dyspnoea (%)134 (99)Increased sputum volume (%)88 (65)Increased sputum purulence (%)81 (60)Increased cough (%)105 (77)Nasal discharge/congestion (%)75 (55)Wheeze (%)110 (81)Sore throat (%)34 (25)Fever (%)[a](#tblfn4){ref-type="table-fn"}38 (28)Anthonisen score[b](#tblfn5){ref-type="table-fn"}1.8 ± 0.8Total symptom score4.6 ± 1.5MRC score5.0 (5.0--5.0)[^4][^5][^6]

Respiratory virus detection {#sec3.4}
---------------------------

Respiratory viruses were detected in sputum and nasal/throat swabs in 50 of 136 (37%) patients during exacerbations of COPD and 8 of 68 (12%) stable COPD patients (*p*  \< 0.0001) ([Table 4](#tbl4){ref-type="table"} ). The viruses detected ([Table 5](#tbl5){ref-type="table"} ) were rhinovirus (57%), adenovirus (18%), parainfluenza 3 (9%), Influenza A H3 (5%), RSV B (3.5%), metapneumovirus (3.5%), coronavirus (2%) and RSV A (2%). There were dual infections in six cases however these were all confined to the exacerbated COPD group. A respiratory virus was more frequently detected during exacerbations in patients with more severe airways disease, *p*  \< 0.05 ([Table 6](#tbl6){ref-type="table"} ). No associations were seen between viral infection and patient sex or medication (use of theophylline or inhaled steroid therapy).Table 4Respiratory viral infection group comparisonsGroupsOdds ratio (95% CI)Relative risk (95% CI)*p* valueExacerbated vs stable4.4 (1.8--10.8)3.1 (1.6--6.2)0.0002Stable vs NOS[a](#tblfn7){ref-type="table-fn"}0.9 (0.2--7.2)0.9 (0.2--4.0)0.93[^7]Table 5Respiratory viral infectionVariablePatient groupExacerbated COPDStable COPDNon-obstructed smokersNo. patients1366816Respiratory viral screen positive (%)50 (36.8)[a](#tblfn6){ref-type="table-fn"}8 (11.8)2 (12.5)Rhinovirus3230Adenovirus1041Influenza A H1000Influenza A H3300Influenza B000Metapneumovirus200Parainfluenza 1000Parainfluenza 2000Parainfluenza 3501Coronavirus110RSV A100RSV B200  Dual infectionsFlu A H3 and Adv200Rhinovirus and adenovirus200Rhinovirus and parainfluenza 3200[^8]Table 6Respiratory viral infection and COPD stageGOLD StageRespiratory virus screen statusRespiratory virus positive (%)Respiratory virus negative10 (0)1211 (31)24316 (31)35423 (47)[a](#tblfn8){ref-type="table-fn"}26[^9]

Discussion {#sec4}
==========

The main findings of this study were that respiratory viruses were more frequently detected during acute exacerbations of COPD in patients admitted to hospital and that CRP levels correlated with exacerbation and duration of hospital stay. This study was performed over a 2-year period in order to avoid bias due to seasonality.

The detection rate of respiratory viruses during exacerbations of COPD in this study (37%) is comparable to results obtained by Seemungal et al. (39.2%)[@bib8] and Beckham et al. 41.8%)[@bib10] but less than the findings of Rohde et al. (56%).[@bib9] Lower detection rates may be related to time of sampling as patients presenting to hospital had developed symptoms for a median of 5 days prior to admission.

This is the first study to prospectively analyse this range of respiratory viruses in patients recruited during exacerbation of COPD. The most common infecting agent was rhinovirus in keeping with previous studies,[@bib8], [@bib9], [@bib10] however we also detected a high rate of adenoviral infection which has not previously been reported. This is in keeping with the findings of Coyle et al. who demonstrated that adenovirus is more commonly detected using PCR than conventional immunofluorescence and virus culture techniques.[@bib14] Previous investigators have related adenoviral infection to subsequent latent infection in the form of adenovirus E1A and that it may be important in the pathogenesis of COPD.[@bib15]

Metapneumovirus was discovered in 2001 and initially detected in young children with a respiratory tract illness.[@bib16] It was subsequently found to play a role in community-acquired respiratory tract illness with 2.2% of patients presenting with 'influenza-like illness' testing positive.[@bib17] Beckham et al. tested specimens from patients during exacerbations of COPD and when stable for metapneumovirus but all patients were negative.[@bib10] Rohde et al. found metapneumovirus to be present in 2.3% of patients during acute exacerbations of COPD and none of the stable COPD patients in keeping with the findings of this study.[@bib18] The detection of human metapneumovirus in this study confirms its role as a respiratory pathogen in adult patients with COPD.

The study showed relatively lower detection rates of influenza virus compared to other studies.[@bib8], [@bib9], [@bib10] This may be related to improved vaccination amongst this group of at risk individuals and it may also reflect that during recruitment for this study there was no influenza epidemic. There was also a lower incidence of RSV infection (3 cases). Previous investigators have suggested that it is more common. Some have suggested that it is present in low copy numbers. It is possible that a more sensitive real-time PCR assay is required in order to detect it.[@bib8] However a recent study suggests that RSV accounted for 11.4% of COPD admissions in hospitalised patients.[@bib19]

This is the first study to also include a group of patients from the same community who do not have respiratory disease (non-obstructed smokers). There were similar detection rates of respiratory viruses in the stable COPD (11.8%) and NOS groups (12.5%) supporting previous findings which found respiratory viral infection to be present in asymptomatic individuals.[@bib6] The frequency of detection in these groups suggests that COPD patients do not have a higher carriage rate of viral infections to NOS but a larger study is required in order to confirm this.

One of the weaknesses of this study was that patients were recruited following admission to hospital. In some cases there may be several days between infection, development of symptoms and presentation. Depending on the duration of viral infection prior to seeking medical help there may be some cases in which patients present late and thus viral replication is decreasing, resulting in a reduced detection rate. This may lead to an underestimation of the prevalence of viral infection in these patients. Recent publications also suggest that RSV detection is increased with the use of real-time PCR assays.[@bib8] All respiratory viral assays in this study utilized nested PCR technology and not real-time PCR methods. Detection of respiratory viruses by PCR may in fact relate to airway colonization[@bib20] or viral persistence.[@bib21] However, several of the patients were seen at different time points during this study and the same virus was not detected by repeat sampling suggesting that those testing positive using the PCR screen were experiencing an acute viral infection.

Another possible confounding factor is that patients with COPD experience exacerbations in which no precipitating agent can be identified. These episodes may be related to the progressive nature of this disease process rather than an acute event. Thus the true role of respiratory viral infection in exacerbations may be under-estimated. A possible area of bias was that all patients recruited were hospitalized. Thus selection bias may have been imposed in that those patients admitted to hospital tended to have particular types of respiratory viral infection or that respiratory viral infection only precipitated an exacerbation and subsequent hospital admission in patients with severe COPD. Another potential source of bias is the seasonality of respiratory viral infection. We addressed this issue by recruiting patients during all months of the year over a 2-year period. Other potential sources of bias include patient selection; those patients most ill and requiring non-invasive ventilation were too ill to participate in the study.

Thompson et al. have published data linking influenza and RSV infection with increased mortality in the elderly.[@bib22] There are increased admissions in older people in winter. Fleming showed that acute respiratory infections are associated with hospitalisation and increased mortality.[@bib23] It reinforces the health service implications of winter infection and increased exacerbations of COPD. It is also noteworthy that the peak death rate is in patients diagnosed with acute respiratory disease.[@bib23] Influenza has been linked with increased health care use by the elderly and there is an excess mortality particularly in the elderly.[@bib24] This paper highlights the impact of respiratory viral infection on health care resources. It supports the use of influenza vaccination in patients with underlying respiratory disease in order to reduce exacerbations and hospital admissions.

In conclusion this study supports the hypothesis that respiratory viral infection is associated with exacerbations of COPD. Rhinovirus was the most common infecting agent identified and in two cases human metapneumovirus was also detected. Dual infections were only seen amongst those patients admitted to hospital with acute exacerbations of COPD. The development of multiplexed real-time PCR assays will enable this technology to be utilized in an acute diagnostic setting.
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[^1]: Exacerbated versus stable; *p* = 0.21, 95% CI −3.3--14.9.

[^2]: Stable COPD versus NOS; *p* = 0.66, 95% CI −15.6--10.1.

[^3]: COPD exacerbation versus stable COPD; *p* \< 0.0001.

[^4]: Symptom score is based on the sum value of binary coded respiratory symptoms: dyspnoea, increased sputum purulence, increased sputum volume, nasal discharge/congestion, wheeze, sore throat and cough.

[^5]: Chi squared test, fever and respiratory virus detection, *p* \< 0.01.

[^6]: Anthonisen criteria.[@bib13]

[^7]: Non-obstructed smokers (NOS), patients who have smoked but who have normal spirometry.

[^8]: *p* \< 0.0005 (respiratory viral detection in exacerbated versus stable COPD).

[^9]: Chi squared test, comparison of groups 1--3 with group 4, linear-by-linear association *p* \< 0.05.
